GB9925559D0 - Novel method - Google Patents

Novel method

Info

Publication number
GB9925559D0
GB9925559D0 GBGB9925559.8A GB9925559A GB9925559D0 GB 9925559 D0 GB9925559 D0 GB 9925559D0 GB 9925559 A GB9925559 A GB 9925559A GB 9925559 D0 GB9925559 D0 GB 9925559D0
Authority
GB
United Kingdom
Prior art keywords
novel method
novel
method
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9925559.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Biologicals SA
Original Assignee
SmithKline Beecham Biologicals SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Biologicals SA filed Critical SmithKline Beecham Biologicals SA
Priority to GBGB9925559.8A priority Critical patent/GB9925559D0/en
Publication of GB9925559D0 publication Critical patent/GB9925559D0/en
Priority claimed from US10/818,819 external-priority patent/US20040191834A1/en
Application status is Ceased legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6068Other bacterial proteins, e.g. OMP
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y02A50/46Medical treatment of waterborne diseases characterized by the agent
    • Y02A50/468The waterborne disease being caused by a bacteria
    • Y02A50/481The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis
    • Y02A50/483The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis the bacteria being Salmonella typhi, i.e. Typhoid fever
    • Y02A50/484The waterborne disease being caused by a bacteria of the genus Salmonella, i.e. Salmonellosis the bacteria being Salmonella typhi, i.e. Typhoid fever the medicinal preparation containing antigens or antibodies, e.g. vaccines, antisera
GBGB9925559.8A 1999-10-28 1999-10-28 Novel method Ceased GB9925559D0 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GBGB9925559.8A GB9925559D0 (en) 1999-10-28 1999-10-28 Novel method

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9925559.8A GB9925559D0 (en) 1999-10-28 1999-10-28 Novel method
PCT/EP2000/010733 WO2001030390A2 (en) 1999-10-28 2000-10-27 Method
JP2001532807A JP2003512440A (en) 1999-10-28 2000-10-27 New method
AU18549/01A AU1854901A (en) 1999-10-28 2000-10-27 Novel method
CA002388995A CA2388995A1 (en) 1999-10-28 2000-10-27 Method
EP00981226A EP1223987A2 (en) 1999-10-28 2000-10-27 Method
US10/818,819 US20040191834A1 (en) 1999-10-28 2004-04-06 Novel method

Publications (1)

Publication Number Publication Date
GB9925559D0 true GB9925559D0 (en) 1999-12-29

Family

ID=10863574

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9925559.8A Ceased GB9925559D0 (en) 1999-10-28 1999-10-28 Novel method

Country Status (6)

Country Link
EP (1) EP1223987A2 (en)
JP (1) JP2003512440A (en)
AU (1) AU1854901A (en)
CA (1) CA2388995A1 (en)
GB (1) GB9925559D0 (en)
WO (1) WO2001030390A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227613B1 (en) 2000-06-29 2011-09-28 Glaxosmithkline Biolog Sa Vaccine composition
SI21352A (en) 2001-01-23 2004-06-30 Aventis Pasteur Multivalent meningococcal polysaccharide-protein conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
GB0211118D0 (en) * 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
ES2608048T3 (en) 2002-10-11 2017-04-05 Glaxosmithkline Biologicals Sa Polypeptide vaccines for broad protection against hypervirulent meningococcal lineages
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CN102302776B (en) 2003-01-30 2014-06-18 诺华疫苗和诊断有限公司 Injectable vaccines against multiple meningococcal serogroups
DE602004032481D1 (en) 2003-10-02 2011-06-09 Novartis Vaccines & Diagnostic combination vaccines against meningitis
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
US8227403B2 (en) 2003-12-17 2012-07-24 Wyeth Llc A-β immunogenic peptide carrier conjugates and methods of producing same
LT2351578T (en) 2005-06-27 2017-04-10 Glaxosmithkline Biologicals S.A. Process for manufacturing vaccines
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
CN103357003A (en) 2006-09-07 2013-10-23 葛兰素史密丝克莱恩生物有限公司 Vaccine
AR066376A1 (en) 2007-05-02 2009-08-12 Glaxosmithkline Biolog Sa Vaccine
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
NZ587382A (en) 2008-02-21 2012-01-12 Novartis Ag Meningococcal fhbp polypeptides
US20100189737A1 (en) 2008-12-17 2010-07-29 Arico Beatrice Meningococcal vaccines including hemoglobin receptor
EP2411045A1 (en) 2009-03-24 2012-02-01 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
JP2013502918A (en) 2009-08-27 2013-01-31 ノバルティス アーゲー Hybrid polypeptide comprising Neisseria meningitidis fHBP sequence
CN102724988B (en) 2009-09-30 2014-09-10 诺华股份有限公司 Expression of meningococcal fHBP polypeptides
WO2011051893A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
EP2613805B1 (en) 2010-09-10 2019-10-23 GlaxoSmithKline Biologicals SA Meningococcus overexpressing nada and/or nhba and outer membrane vesicles derived therefrom
EP2707009A1 (en) 2011-05-12 2014-03-19 Novartis AG Antipyretics to enhance tolerability of vesicle-based vaccines
CN102507924B (en) * 2011-11-17 2014-06-18 成都欧林生物科技股份有限公司 Method for detecting concentration of polysaccharide in zymotic fluid
EP3299467A3 (en) 2012-02-02 2018-05-30 GlaxoSmithKline Biologicals SA Promoters for increased protein expression in meningococcus

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5604108A (en) * 1992-09-14 1997-02-18 Connaught Laboratories, Inc. Test for determining the dose response of a conjugated vaccine
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
PT1163000E (en) * 1999-03-19 2008-03-20 Glaxosmithkline Biolog Sa Vaccine against antigens from bacteriae

Also Published As

Publication number Publication date
JP2003512440A (en) 2003-04-02
WO2001030390A2 (en) 2001-05-03
WO2001030390A3 (en) 2002-04-04
CA2388995A1 (en) 2001-05-03
EP1223987A2 (en) 2002-07-24
AU1854901A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
DE60027300D1 (en) Photoablationssystem
DE60021909D1 (en) Prägeform-lithographie
DE60019094D1 (en) Gastrostimulationsgerät
DE60003001D1 (en) Pyrimidinverbindungen
DE60030160D1 (en) Facelifting-gerät
DE50015635D1 (en) Bstraten
DE60017279D1 (en) Pyrimidinderivate
DE60021917D1 (en) Perkutane stentprothese
DE50014113D1 (en) Common-rail-injektor
GB2355413B (en) Handle-gripping
DE60008382D1 (en) Respiratorisches syncytialvirus replikation inhibitoren
DE60030867D1 (en) Ostomie-irrigationssystem
DE60029475D1 (en) Phakische intraokularlinse
DE60037335D1 (en) Polymerizationsverfahren
DE60014588D1 (en) Thioamidderivate
IL147803D0 (en) 28-epirapalogs
PL352251A1 (en) Anti-alphav
DE60018288D1 (en) Polyphenylensulfidlegierungszusammensetzung
DE60029235D1 (en) Fab-i-hemmer
IL147757D0 (en) 2-pyrazolin-5-ones
GB9903830D0 (en) Process-systems integration method
GB9902652D0 (en) Process
SG119194A1 (en) Process
GB9930219D0 (en) Process
GB9902412D0 (en) Process

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)